MedKoo product information:

 Buserelin

buserelin is a synthetic analog of gonadotropin-releasing hormone (GnRH). Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

 1: Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl). 2010 Jan;6(1):27-35. Review. PubMed PMID: 20001868.

2: Thitaram C, Pongsopawijit P, Chansitthiwet S, Brown JL, Nimtragul K, Boonprasert K, Homkong P, Mahasawangkul S, Rojanasthien S, Colenbrander B, van der Weijden GC, van Eerdenburg FJ. Induction of the ovulatory LH surge in Asian elephants (Elephas maximus): a novel aid in captive breeding management of an endangered species. Reprod Fertil Dev. 2009;21(5):672-8. PubMed PMID: 19486604.

3: Taguchi T, Noguchi S. [Clinical applications of GnRHa in breast cancer]. Nippon Rinsho. 2006 Apr;64 Suppl 4:85-9. Review. Japanese. PubMed PMID: 16689290.

4: Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grøndahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006 Aug;21(8):2126-30. Epub 2006 May 8. PubMed PMID: 16682403.

5: Proos LA, Lönnerholm T, Jonsson B, Tuvemo T. Can bone age determination provide criteria for growth hormone treatment in adopted girls with early puberty? Ups J Med Sci. 2006;111(1):117-29. PubMed PMID: 16553251.

6: Kanitz W, Schneider F, Hoppen HO, Unger C, Nürnberg G, Becker F. Pregnancy rates, LH and progesterone concentrations in mares treated with a GnRH agonist. Anim Reprod Sci. 2007 Jan;97(1-2):55-62. Epub 2006 Feb 20. PubMed PMID: 16488561.

7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Dec;27(10):711-38. PubMed PMID: 16395422.

8: Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol. 2005 Feb;12(1):2547-52. PubMed PMID: 15777493.

9: Tenhagen BA, Surholt R, Wittke M, Vogel C, Drillich M, Heuwieser W. Use of Ovsynch in dairy herds--differences between primiparous and multiparous cows. Anim Reprod Sci. 2004 Mar;81(1-2):1-11. PubMed PMID: 14749044.

10: Out HJ, Mannaerts BM. The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data. Hum Fertil (Camb). 2002 Feb;5(1):G5-10; discussion G10-2, G41-8. Review. PubMed PMID: 11939160.

11: Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002 Apr;17(4):874-85. PubMed PMID: 11925376.

12: Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2001;(4):CD001750. Review. Update in: Cochrane Database Syst Rev. 2006;3:CD001750. PubMed PMID: 11687120.

13: Tenhagen BA, Drillich M, Heuwieser W. Analysis of cow factors influencing conception rates after two timed breeding protocols. Theriogenology. 2001 Sep 15;56(5):831-8. PubMed PMID: 11665885.

14: Barrier-Battut I, Le Poutre N, Trocherie E, Hecht S, Grandchamp des Raux A, Nicaise JL, Vérin X, Bertrand J, Fiéni F, Hoier R, Renault A, Egron L, Tainturier D, Bruyas JF. Use of buserelin to induce ovulation in the cyclic mare. Theriogenology. 2001 May 1;55(8):1679-95. PubMed PMID: 11393219.

15: Newcombe JR, Martinez TA, Peters AR. The effect of the gonadotropin-releasing hormone analog, buserelin, on pregnancy rates in horse and pony mares. Theriogenology. 2001 May 1;55(8):1619-31. PubMed PMID: 11393215.

16: Ortmann O, Weiss JM, Diedrich K. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Hum Reprod. 2001 Apr;16(4):608-11. Review. PubMed PMID: 11278203.

17: Wong JM, Forrest KA, Snabes SZ, Zhao SZ, Gersh GE, Kennedy SH. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update. 2001 Jan-Feb;7(1):92-101. PubMed PMID: 11212082.

18: Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001 Jan 15;19(2):343-53. PubMed PMID: 11208825.

19: Powles TJ. Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000 Dec 20;92(24):2040-2. PubMed PMID: 11121468.

20: Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review. PubMed PMID: 11098244.

21: Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging. 2000 Apr;16(4):261-71. Review. PubMed PMID: 10874521.

22: Davidson NE. Combined endocrine therapy for breast cancer--new life for an old idea? J Natl Cancer Inst. 2000 Jun 7;92(11):859-60. PubMed PMID: 10841814.

23: Xu ZZ, Burton LJ. Estrus synchronization of lactating dairy cows with GnRH, progesterone, and prostaglandin F2 alpha. J Dairy Sci. 2000 Mar;83(3):471-6. PubMed PMID: 10750104.

24: Xu ZZ, Burton LJ, McDougall S, Jolly PD. Treatment of noncyclic lactating dairy cows with progesterone and estradiol or with progesterone, GnRH, prostaglandin F2 alpha, and estradiol. J Dairy Sci. 2000 Mar;83(3):464-70. PubMed PMID: 10750103.

25: Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5. PubMed PMID: 10744594.

26: Lynch PR, Macmillan KL, Taufa VK. Treating cattle with progesterone as well as a GnRH analogue affects oestrous cycle length and fertility. Anim Reprod Sci. 1999 Aug 16;56(3-4):189-200. PubMed PMID: 10497915.

27: Ohta H, Sakamoto H, Satoh K. In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett. 1998 Dec 11;134(1):111-8. PubMed PMID: 10381137.

28: Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol. 1998;33(2):134-43. PubMed PMID: 9519354.

29: Pycock JF, Newcombe JR. The effect of the gonadotrophin-releasing hormone analog, buserelin, administered in diestrus on pregnancy rates and pregnancy failure in mares. Theriogenology. 1996 Oct 15;46(6):1097-101. PubMed PMID: 16727973.

30: Out HJ, Mannaerts BM, Driessen SG, Coelingh Bennink HJ. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies. Hum Reprod Update. 1996 Mar-Apr;2(2):162-71. Review. PubMed PMID: 9079411.

31: da Motta LA, da Motta LD. [Endocrine treatment of meningiomas: a review]. Arq Neuropsiquiatr. 1995 Jun;53(2):324-32. Review. Portuguese. PubMed PMID: 7487548.

32: Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994 Dec;48(6):930-67. Review. PubMed PMID: 7533699.

33: Connor JP, Buller RE, Conn PM. Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol Oncol. 1994 Jul;54(1):80-6. PubMed PMID: 8020844.

34: Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod. 1994 Jun;9 Suppl 1:202-7. Review. PubMed PMID: 7962466.

35: Tapanainen JS, Hovatta O. Pituitary down-regulation with goserelin (Zoladex) for in vitro fertilisation. Br J Obstet Gynaecol. 1994 May;101 Suppl 10:27-8. Review. PubMed PMID: 8199101.

36: Franks S, Gilling-Smith C. Advances in induction of ovulation. Curr Opin Obstet Gynecol. 1994 Apr;6(2):136-40. Review. PubMed PMID: 8193252.

37: Drew SB, Peters AR. Effect of buserelin on pregnancy rates in dairy cows. Vet Rec. 1994 Mar 12;134(11):267-9. PubMed PMID: 8197694.

38: Partsch CJ, Hümmelink R, Sippell WG, Oostdijk W, Odink RJ, Drop SL. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height]. Monatsschr Kinderheilkd. 1993 Dec;141(12):935-9. German. PubMed PMID: 8114776.

39: Vollenhoven BJ, McCloud P, Shekleton P, McDonald J, Healy DL. An open study of luteinizing hormone releasing hormone agonists in infertile women with uterine fibroids. Gynecol Endocrinol. 1993 Mar;7(1):57-61. PubMed PMID: 8506764.

40: Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S, Cutler GB Jr. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatr Suppl. 1993 Mar;388:62-8; discussion 69. Review. PubMed PMID: 8329833.

41: Fraser HM. GnRH analogues for contraception. Br Med Bull. 1993 Jan;49(1):62-72. Review. PubMed PMID: 8324616.

42: Peters AR, Drew SB, Mann GE, Lamming GE, Beck NF. Experimental and practical approaches to the establishment and maintenance of pregnancy. J Physiol Pharmacol. 1992 Dec;43(4 Suppl 1):143-52. PubMed PMID: 1343966.

43: Fleshner NE, Trachtenberg J. Sequential androgen blockade: a biological study in the inhibition of prostatic growth. J Urol. 1992 Dec;148(6):1928-31. PubMed PMID: 1331549.

44: Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):155-9. Review. PubMed PMID: 1388047.

45: Vogelzang NJ, Kennealey GT. Recent developments in endocrine treatment of prostate cancer. Cancer. 1992 Aug 15;70(4 Suppl):966-76. Review. PubMed PMID: 1386283.

46: Bica DT, Hadziselimovic F. Buserelin treatment of cryptorchidism: a randomized, double-blind, placebo-controlled study. J Urol. 1992 Aug;148(2 Pt 2):617-21. PubMed PMID: 1353540.

47: Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Militello C, Pedrazzoli S. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin). Eur J Surg Oncol. 1992 Jun;18(3):267-71. PubMed PMID: 1535051.

48: Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, Blackledge GR. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol. 1992 Jun;69(6):614-20. PubMed PMID: 1386272.

49: Izuo M. [New drugs in endocrine treatment of breast cancer]. Nippon Naibunpi Gakkai Zasshi. 1992 May 20;68(5):538-49. Review. Japanese. PubMed PMID: 1322843.

50: Franssen AM, van der Heijden PF, Thomas CM, Doesburg WH, Willemsen WN, Rolland R. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Fertil Steril. 1992 May;57(5):974-9. PubMed PMID: 1533376.

51: Behre HM, Nashan D, Hubert W, Nieschlag E. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab. 1992 Jan;74(1):84-90. PubMed PMID: 1727833.

52: Huben RP, Perrapato SD. Drug therapy of prostatic cancer. Drugs Aging. 1991 Sep-Oct;1(5):353-63. Review. PubMed PMID: 1838950.

53: Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA. 1991 Feb 6;265(5):618-21. PubMed PMID: 1824790.

54: Denis L, Smith P, Carneiro de Moura JL, Newling D, Bono A, Keuppens F, Mahler C, Robinson M, Sylvester R, De Pauw M, et al. Total androgen ablation: European experience. The EORTC GU Group. Urol Clin North Am. 1991 Feb;18(1):65-73. PubMed PMID: 1825144.

55: Gaillard-Moguilewsky M. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology. 1991;37(2 Suppl):5-12. Review. PubMed PMID: 1992602.

56: Du Plessis DJ. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology. 1991;37(2 Suppl):20-4. Review. PubMed PMID: 1992599.

57: Bianco AR, Rosso R, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, Lenti R, Fosser V, De Placido S, Perrone F, et al. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). Eur J Gynaecol Oncol. 1991;12(6):429-37. PubMed PMID: 1839730.

58: de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):965-9. PubMed PMID: 2149509.

59: Guidez C. [How can a nursing team participate in a clinical trial? Zoladex, flutamide trial]. Soins. 1990 Sep;(540):53. French. PubMed PMID: 2151069.

60: Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer. 1990 Sep 1;66(5 Suppl):1067-73. PubMed PMID: 2144208.

61: Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990 Sep 1;66(5 Suppl):1058-66. PubMed PMID: 2144207.

62: Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, Sylvester R, De Pauw M, Vermeylen K, Ongena P. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. Cancer. 1990 Sep 1;66(5 Suppl):1045-57. PubMed PMID: 2144206.

63: Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer. Cancer. 1990 Sep 1;66(5 Suppl):1029-34. PubMed PMID: 2144205.

64: Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer. 1990 Sep 1;66(5 Suppl):1009-16. PubMed PMID: 2144203.

65: Lejeune B, Barlow P, Puissant F, Delvigne A, Vanrysselberge M, Leroy F. Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment. Fertil Steril. 1990 Sep;54(3):475-81. PubMed PMID: 2118860.

66: Lanzone A, Fulghesu AM, Guida C, Muscatello R, Caruso A, Mancuso S. Serum CA-125 levels do not depend on ovarian steroidogenesis. Fertil Steril. 1990 Sep;54(3):415-8. PubMed PMID: 2118857.

67: Zweers A, De Boever J, Serreyn R, Vandekerckhove D. Correlation between peripheral CA-125 levels and ovarian activity. Fertil Steril. 1990 Sep;54(3):409-14. PubMed PMID: 2118856.

68: Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho AP, Newling D, Bono A, Sylvester R, De Pauw M, et al. Complete androgen blockade: data from an EORTC 30853 trial. Semin Urol. 1990 Aug;8(3):166-74. PubMed PMID: 2144656.

69: Kujala UM, Alen M, Huhtaniemi IT. Gonadotrophin-releasing hormone and human chorionic gonadotrophin tests reveal that both hypothalamic and testicular endocrine functions are suppressed during acute prolonged physical exercise. Clin Endocrinol (Oxf). 1990 Aug;33(2):219-25. PubMed PMID: 2121394.

70: Fedele L, Marchini M, Bianchi S, Baglioni A, Bocciolone L, Nava S. Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study. Obstet Gynecol. 1990 Jul;76(1):79-84. PubMed PMID: 2113661.

71: Fedele L, Vercellini P, Bianchi S, Brioschi D, Dorta M. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol. 1990 May;97(5):393-6. PubMed PMID: 2115379.

72: Herrick AL, McColl KE, Wallace AM, Moore MR, Goldberg A. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med. 1990 Apr;75(276):355-63. PubMed PMID: 2117297.

73: Emtage LA, George J, Boughton BJ, Trethowan C, Blackledge GR. Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month. Eur J Cancer. 1990 Mar;26(3):315-9. PubMed PMID: 2141488.

74: Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril. 1990 Mar;53(3):473-8. PubMed PMID: 2106453.

75: Schenken RS. Gonadotropin-releasing hormone analogs in the treatment of endometriomas. Am J Obstet Gynecol. 1990 Feb;162(2):579-81. PubMed PMID: 2137974.

76: Johnson P, Pearce JM. Recurrent spontaneous abortion and polycystic ovarian disease: comparison of two regimens to induce ovulation. BMJ. 1990 Jan 20;300(6718):154-6. Retraction in: BMJ. 1995 Jul 22;311(6999):231. PubMed PMID: 2105793; PubMed Central PMCID: PMC1662188.

77: Di Silverio F, Sciarra F, D'Eramo G. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate. Eur Urol. 1990;18(1):10-5. PubMed PMID: 2144819.

78: Donnez J, Nisolle M, Clerckx F, Casanas F. Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserelin spray and buserelin implant, in the treatment of endometriosis associated infertility. Prog Clin Biol Res. 1990;323:427-42. PubMed PMID: 2106147.

79: Trabant H, Widdra W, de Looze S. Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol. Prog Clin Biol Res. 1990;323:357-82. Review. PubMed PMID: 2106146.

80: Cassano A, Astone A, Garufi C, Noviello MR, Pietrantonio F, Barone C. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex. Cancer Lett. 1989 Nov 30;48(2):123-4. PubMed PMID: 2555044.

81: Camier B, Gagneur O, Arlot S, Thépot F, Vitse M. [Preliminary study of the use of intranasal buserelin in the long-term protocol of ovarian stimulation with the view toward fertilization in vitro]. Rev Fr Gynecol Obstet. 1989 Oct;84(10):659-61. French. PubMed PMID: 2510234.

82: Macnamee MC, Howles CM, Edwards RG, Taylor PJ, Elder KT. Short-term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization. Fertil Steril. 1989 Aug;52(2):264-9. PubMed PMID: 2502441.

83: Smith EM, Anthony FW, Gadd SC, Masson GM. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. BMJ. 1989 Jun 3;298(6686):1483-6. PubMed PMID: 2503080; PubMed Central PMCID: PMC1836668.

84: Cheson BD. Clinical trials referral resource. Adjuvant therapy of breast cancer. Oncology (Williston Park). 1989 Jun;3(6):70-1, 74-5, 78. PubMed PMID: 2534915.

85: MacLachlan V, Besanko M, O'Shea F, Wade H, Wood C, Trounson A, Healy DL. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N Engl J Med. 1989 May 11;320(19):1233-7. PubMed PMID: 2496310.

86: Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology. 1989 May;33(5 Suppl):45-52. PubMed PMID: 2523611.

87: Chodak GW. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. Urology. 1989 May;33(5 Suppl):42-4. Review. PubMed PMID: 2523610.

88: Waxman JH, Sandow J, Abel P, Farah N, O'Donoghue EP, Fleming J, Cox J, Sikora K, Williams G. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol (Copenh). 1989 Mar;120(3):315-8. PubMed PMID: 2494825.

89: Kiesel L, Bertges K, von Holst TR, Runnebaum B. [Treatment of endometriosis]. Arch Gynecol Obstet. 1989;245(1-4):937-40. German. PubMed PMID: 2679444.

90: Tyrrell C. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer. Horm Res. 1989;32 Suppl 1:218-20. PubMed PMID: 2533154.

91: Turkes AO, Griffiths K. Endocrine treatment of prostate cancer. Prog Med Chem. 1989;26:299-321. Review. PubMed PMID: 2532376.

92: Waxman J. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer. Prog Clin Biol Res. 1989;303:61-8. PubMed PMID: 2528741.

93: Emtage LA, Trethowan C, Kelly K, Arkell D, Wallace DM, Hughes M, Hay A, Blacklock R, Jones M, Rouse A, et al. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study. Prog Clin Biol Res. 1989;303:47-52. PubMed PMID: 2528739.

94: Peeling WB. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate. Prog Clin Biol Res. 1989;303:41-5. PubMed PMID: 2528738.

95: Lunglmayr G. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group. Prog Clin Biol Res. 1989;303:145-51. PubMed PMID: 2528737.

96: Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, Sylvester R, De Pauw M, Ongena P. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group. Prog Clin Biol Res. 1989;303:129-43. PubMed PMID: 2528736.

97: Rönnberg L, Koskimies A, Laatikainen T, Ranta T, Saastamoinen J. Efficacy of gonadotropin-releasing hormone agonist (buserelin) in the treatment of endometriosis. Acta Obstet Gynecol Scand. 1989;68(1):49-53. PubMed PMID: 2508418.

98: Roila F. Buserelin in the treatment of prostatic cancer. Biomed Pharmacother. 1989;43(4):279-85. Review. PubMed PMID: 2506941.

99: Koiter TR, Moes H, Schuiling GA. Commercially available analogues of GnRH and LH secretion. Acta Endocrinol (Copenh). 1988 Nov;119(3):345-52. PubMed PMID: 2973201.

100: Nakamura Y, Yoshimura Y, Tamaoka Y, Ubukata Y, Yoshida K, Yamada H, Iizuka R, Suzuki M. Treatment of polycystic ovarian disease by inducing ovulation with pulsatile subcutaneous administration of human menopausal gonadotrophin associated with luteinizing hormone-releasing hormone analogue. Clin Endocrinol (Oxf). 1988 Oct;29(4):395-402. PubMed PMID: 3150824.

101: Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Akaza H, Niijima T, Aso Y, Araki T, Itatani H, et al. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen]. Hinyokika Kiyo. 1988 Oct;34(10):1853-63. Japanese. PubMed PMID: 2977527.

102: Badenoch DF, Waxman J, Boorman L, Sidhu B, Moore HD, Holt WV, Blandy JP. Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males. Acta Endocrinol (Copenh). 1988 Feb;117(2):265-7. PubMed PMID: 3132792.

103: Sandow J, von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol. 1988;11 Suppl 1:S6-10. Review. PubMed PMID: 3291602.

104: Hammarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67(2):159-66. PubMed PMID: 3140572.

105: Soloway MS. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls. Am J Clin Oncol. 1988;11 Suppl 1:S29-32. PubMed PMID: 3133944.

106: Waxman J. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer. Am J Clin Oncol. 1988;11 Suppl 1:S16-8. PubMed PMID: 3133943.

107: Emtage LA, Trethowan C, Hilton C, Kelly K, Blackledge GR. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group. Am J Clin Oncol. 1988;11 Suppl 2:S173-5. PubMed PMID: 2977273.

108: Ryan PG, Peeling WB. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy. Am J Clin Oncol. 1988;11 Suppl 2:S169-72. PubMed PMID: 2977272.

109: Javadpour N. Selected advances in therapy of urologic cancer--luteinizing hormone releasing hormone (LHRH) and biologic response modifier (BUR). Prog Clin Biol Res. 1988;277:27-38. PubMed PMID: 2973069.

110: Lunglmayr G, Girsch E, Meixner EM, Viehberger G, Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res. 1988;16(4):315-9. PubMed PMID: 2972102.

111: Jacobi GH, Wenderoth UK, Ehrenthal W, von Wallenberg H, Spindler HW, Hohenfellner R. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment. Am J Clin Oncol. 1988;11 Suppl 1:S36-43. PubMed PMID: 2968761.

112: Debruyne FM. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Am J Clin Oncol. 1988;11 Suppl 1:S33-5. PubMed PMID: 2968760.

113: Borgmann V, al-Abadi H, Nagel R. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results. Am J Clin Oncol. 1988;11 Suppl 1:S19-28. PubMed PMID: 2968759.

114: Kaisary AV, Ryan PG, Turkes A, Peeling WB, Griffiths K. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study. Prog Clin Biol Res. 1988;260:89-100. PubMed PMID: 2966408.

115: Debruyne FM, Fernandez del Moral P, Geboers AD. LHRH-analogues therapy for metastatic prostate cancer. Prog Clin Biol Res. 1988;260:27-39. PubMed PMID: 2966406.

116: Da Silva FC, Aaronson N. Quality of life assessment in prostatic cancer. Prog Clin Biol Res. 1988;260:119-21. PubMed PMID: 2966404.

117: Swanson LJ, Seely JH, Garnick MB. Gonadotropin-releasing hormone analogs and prostatic cancer. Crit Rev Oncol Hematol. 1988;8(1):1-26. Review. PubMed PMID: 2964939.

118: Emtage LA, Lewis PW, Blackledge GR. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer. Br J Urol. 1987 Dec;60(6):572-7. PubMed PMID: 2447997.

119: Emtage LA, Perren TJ, Stuart NS, Arkell DG, Wallace DM, Hughes MA, Cottam J, Farrar D, Young CH, Blackledge GR. Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival. Br J Urol. 1987 Nov;60(5):436-42. PubMed PMID: 2962689.

120: Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, Cristol P, Viala JL. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril. 1987 Apr;47(4):639-43. PubMed PMID: 3106101.

121: Fraser HM, Baird DT. Clinical applications of LHRH analogues. Baillieres Clin Endocrinol Metab. 1987 Feb;1(1):43-70. Review. PubMed PMID: 3109366.

122: Maheux R, Lemay A, Merat P. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil Steril. 1987 Feb;47(2):229-33. PubMed PMID: 3102282.

123: Murphy GP, Greco JM, Chin JL, Huben RP, Scott M, deHaan HA. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma. Urology. 1987 Feb;29(2):185-90. PubMed PMID: 2949417.

124: Franks S, Sagle M, Mason HD, Kiddy D. Use of LHRH agonists in the treatment of anovulation in women with polycystic ovary syndrome. Horm Res. 1987;28(2-4):164-8. PubMed PMID: 3136067.

125: Navratil H. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Prog Clin Biol Res. 1987;243A:401-10. PubMed PMID: 3116551.

126: Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Venner PM, Tewari HD. Total androgen blockade vs orchiectomy in stage D2 prostate cancer. Prog Clin Biol Res. 1987;243A:391-400. PubMed PMID: 3116550.

127: Turkes AO, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group. J Steroid Biochem. 1987;27(1-3):543-9. PubMed PMID: 2961938.

128: Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem. 1986 Nov;25(5B):877-83. PubMed PMID: 3100871.

129: Bouffioux C, Focan C, Désirotte J, Andrianne R, de Leval J, Doupagne M, Franchimont P. [Treatment of cancer of the prostate with Zoladex Depot]. Rev Med Liege. 1986 May 15;41(10):438-45. French. PubMed PMID: 2943011.

130: McLachlan RI, Healy DL, Burger HG. Clinical aspects of LHRH analogues in gynaecology: a review. Br J Obstet Gynaecol. 1986 May;93(5):431-54. Review. PubMed PMID: 3085705.

131: de Voogt HJ. [Prostate cancer; hormonal treatment in a new stage?]. Ned Tijdschr Geneeskd. 1986 Apr 26;130(17):766-8. Dutch. PubMed PMID: 2423887.

132: Eisenberger MA, O'Dwyer PJ, Friedman MA. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol. 1986 Mar;4(3):414-24. Review. PubMed PMID: 2936872.

133: Hompes PG, van Weissenbruch MM, Burger CW, Schoemaker J. The additional use of buserelin in HMG-HCG ovulation induction in PCO: a double blind controlled study. Prog Clin Biol Res. 1986;225:391-9. PubMed PMID: 3097674.

134: Hoffmann G, Schommer M, Pollow K, von der Ohe M. LHRH agonist and contraception. Prog Clin Biol Res. 1986;225:325-35. PubMed PMID: 3097671.

135: Jelley RY, Magill PJ. The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Prog Clin Biol Res. 1986;225:227-38. PubMed PMID: 3097668.

136: Minaguchi H, Uemura T, Shirasu K. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Prog Clin Biol Res. 1986;225:211-25. PubMed PMID: 3097667.

137: Franssen AM, Kauer FM, Rolland R, Zijlstra JA, Willemsen WN, van 't Veen AJ. The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience). Prog Clin Biol Res. 1986;225:201-10. PubMed PMID: 3097666.

138: Cirkel U, Schweppe KW, Ochs H, Schneider HP. Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience). Prog Clin Biol Res. 1986;225:189-99. PubMed PMID: 3097665.

139: Yee B. A preliminary report on the comparative use of buserelin (Hoe 766) and danazol in the treatment of endometriosis: the University of Southern California experience. Prog Clin Biol Res. 1986;225:175-88. PubMed PMID: 3097664.

140: Weinbauer GF, Nieschlag E. Regulation of primate testicular function by GnRH analogues. Med Biol. 1986;63(5-6):210-7. PubMed PMID: 3084885.

141: Mathé G, Schally AV, Comaru-Schally AM, Mauvernay RY, Vovan ML, Machover D, Misset JL, Court B, Bouchard P, Duchier J, et al. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. Prostate. 1986;9(4):327-42. PubMed PMID: 2947053.

142: Nillius SJ. Gonadotrophin-releasing hormone agonists for new approaches to contraception in man. Wien Klin Wochenschr. 1985 Dec 6;97(23):865-73. Review. PubMed PMID: 3934848.

143: Iglesias Cortit L. [New advances in contraception and sterilization]. Med Clin (Barc). 1985 Nov 2;85(14):588-95. Review. Spanish. PubMed PMID: 3908850.

144: Pepperell RJ. Will gonadotrophin releasing hormone analogues profoundly affect gynaecological practice? Aust N Z J Obstet Gynaecol. 1985 Nov;25(4):285-8. PubMed PMID: 3938950.

145: Vijayan E. Recent developments in female contraception: LHRH. J Steroid Biochem. 1985 Nov;23(5B):827-31. PubMed PMID: 3935868.

146: Nseyo UO, Huben RP, Klioze SS, Pontes JE. Protection of germinal epithelium with luteinizing hormone-releasing hormone analogue. J Urol. 1985 Jul;134(1):187-90. PubMed PMID: 3925164.

147: Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections. Eur J Surg Oncol. 1985 Jun;11(2):159-65. PubMed PMID: 3159598.

148: Hollander V. Prostate cancer: clinical trials of gonadotrophin-releasing hormone analogs as an alternative to orchiectomy. Mt Sinai J Med. 1985 Mar;52(3):205-6. PubMed PMID: 3921828.

149: Koutsilieris M, Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. Prostate. 1985;7(1):31-9. PubMed PMID: 3936031.

150: Faure N, Lemay A. Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men. Arch Androl. 1985;14(2-3):95-106. PubMed PMID: 2933008.

151: Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984 Dec 1;2(8414):1284-5. PubMed PMID: 6150318.

152: Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984 Nov;24(5 Suppl):30-8. PubMed PMID: 6437034.

153: Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex). J Endocrinol. 1984 Nov;103(2):R1-4. PubMed PMID: 6238116.

154: Thau RB. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review. Contraception. 1984 Feb;29(2):143-62. Review. PubMed PMID: 6426857.

155: Klijn JG, de Jong FH, Blankenstein MA, Docter R, Alexieva-Figusch J, Blonk-van der Wijst J, Lamberts SW. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer. Breast Cancer Res Treat. 1984;4(3):209-20. PubMed PMID: 6435703.

156: Waxman JH, Wass JA, Hendry WF, Whitfield HN, Bary P, Besser GM, Malpas JS, Oliver RT. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone. Br J Urol. 1983 Dec;55(6):737-42. PubMed PMID: 6418264.

157: Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas AT. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate. 1983;4(6):601-24. PubMed PMID: 6415632.

158: Kerr-Wilson RH, MacKenzie L, Fraser HM. Effects of chronic LHRH agonist treatment on the endometrium and ovaries of the stumptailed macaque. Contraception. 1981 Dec;24(6):647-55. PubMed PMID: 6799243.